Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Revenue increased due to the expansion of domestic partner medical institutions, increases in the number of U.S. locations and patients in the lower-extremity venous disease field, the inclusion of a newly consolidated OBL operator, contributions from new facilities and locations, an increase in the number of users, and higher prices, utilization rates and unit prices. Profit declined due to upfront investment, higher personnel and recruitment expenses, lower unit prices following the revision of medical service fees, initial losses at new locations, and higher finance costs resulting from increased borrowings and rising interest rates.
None ("There are no applicable matters.")
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥28,735 million (YoY +9.3%) |
| Operating profit | ¥947 million (YoY -44.7%) |
| Ordinary income | ¥446 million (YoY -68.1%) |
| Profit attributable to owners of the parent | ¥-101 million |
| Net income per share | -¥3.45 |
| Equity ratio | End of the current fiscal period 33.5 / End of previous period 34.1 |
| Total assets | ¥100,838 million |
| Net assets | ¥34,092 million |
| Cash and cash equivalents at end of period | ¥16,120 million |
| Full-year earnings forecast | Net Sales ¥64,600 million (YoY +18.9%) / Operating profit ¥3,800 million (YoY -34.3%) / Ordinary income ¥2,800 million (YoY -45.2%) / Net income ¥1,100 million (YoY -59.9%) |
| Revision to Earnings Forecast | No revision |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Segment revenue | Medical institutions ¥9,544 million (YoY +16.0%), Hospice ¥8,644 million (YoY +8.9%), Home-Visit Nursing ¥6,732 million (YoY +3.3%), Medical Care Residences ¥3,880 million (YoY +7.2%) |
| Segment profit | Medical institutions ¥1,353 million (YoY -8.3%), Hospice ¥-227 million, Home-Visit Nursing ¥422 million (YoY -35.7%), Medical Care Residences ¥-73 million |
| Depreciation and amortization | ¥2,816 million |
| Disclosure regarding the going concern assumption | None ("There are no applicable matters.") |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New 0 / Excluded 0 / Company name Not applicable |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Not disclosed |
| Issued Shares at Period-End | 29,990,400 shares |
| Treasury Shares at Period-End | 675,124 shares |
| Factors Behind Changes in Business Performance | Revenue increased due to the expansion of domestic partner medical institutions, increases in the number of U.S. locations and patients in the lower-extremity venous disease field, the inclusion of a newly consolidated OBL operator, contributions from new facilities and locations, an increase in the number of users, and higher prices, utilization rates and unit prices. Profit declined due to upfront investment, higher personnel and recruitment expenses, lower unit prices following the revision of medical service fees, initial losses at new locations, and higher finance costs resulting from increased borrowings and rising interest rates. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased due to the expansion of domestic partner medical institutions, increases in the number of U.S. locations and patients, contributions from new facilities, an increase in the number of users, and higher prices, utilization rates and unit prices. Profit was affected by upfront investment for the opening of U.S. OBL facilities, lower unit prices following the revision of medical service fees, higher personnel and recruitment expenses due to the early hiring of staff, initial losses at new locations, and higher finance costs resulting from increased borrowings and rising interest rates.